Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1117"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:Evidence_value |
"0.96"
|
| ?:content |
"Absorption
The pharmacokinetic properties of voriconazole are similar following administration by the intravenous and oral routes. Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%). Bioequivalence was established between the 200 mg tablet and the 40 mg/mL oral suspension when administered as a 400 mg Q12h loading dose followed by a 200 mg Q12h maintenance dose."
|
| dc:creator | |
| dc:date |
"09/24/2009 15:01:25"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ voriconazole_bioavailability_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1020 }